EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2001-1326
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer ; volume:8 ; number:1 ; day:19 ; month:1 ; year:2019 ; pages:1-18 ; date:12.2019
Clinical and translational medicine ; 8, Heft 1 (19.1.2019), 1-18, 12.2019
- Urheber
-
Phan, Thang Thanh
Tran, Bich-Thu
Nguyen, Son Truong
Ho, Toan Trong
Nguyen, Hang Thuy
Le, Vu Thuong
Le, Anh Tuan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40169-019-0219-8
- URN
-
urn:nbn:de:101:1-2019022223415058754269
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Phan, Thang Thanh
- Tran, Bich-Thu
- Nguyen, Son Truong
- Ho, Toan Trong
- Nguyen, Hang Thuy
- Le, Vu Thuong
- Le, Anh Tuan
- SpringerLink (Online service)
Ähnliche Objekte (12)
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
Reduzierte Dosis von TKI führt nicht zu Wirkungsverlust bei Patienten mit aktivierender EGFR-Mutation
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
Reduzierte Dosis von TKI führt nicht zu Wirkungsverlust bei Patienten mit aktivierender EGFR-Mutation
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer